Logo

Vir Biotechnology Reports the First Patient Dosing in the P-II (SOLSTICE) Trial of VIR-2218 and VIR-3434 for Chronic Hepatitis D Virus Infection

Share this
Vir Biotechnology Reports the First Patient Dosing in the P-II (SOLSTICE) Trial of VIR-2218 and VIR-3434 for Chronic Hepatitis D Virus Infection

Vir Biotechnology Reports the First Patient Dosing in the P-II (SOLSTICE) Trial of VIR-2218 and VIR-3434 for Chronic Hepatitis D Virus Infection

Shots:

  • The first patient has been dosed in the P-II (SOLSTICE) trial evaluating the safety, tolerability & efficacy of VIR-2218 and VIR-3434 as monothx. & in combination with adult patients aged 18 to 69yrs. for chronic HDV for ~88wks. The initial results are expected in 2023
  • The 1EPs of the trial is the proportion of patients who achieve a ≥2log10 decrease in HDV RNA over baseline or HDV RNA less than the limit of quantification & normalization of ALT @24wk. along with a proportion of patients with TEAE & SAEs
  • VIR-2218 & VIR-3434 are also being studied in the P-II (MARCH) trial for HBV. The part A results of the (MARCH) trial showed that the combination therapy resulted in an ~3 log decline in HBsAg

Ref: Globenewswire | Image: Vir Biotechnology

Click here to­ read the full press release 

Neha

Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions